CJC Open · 2020 · 11 citations · 31 references
MedicineCardiologyHealth SciencesClinical CardiologyClinical EpidemiologyEpidemiologyCardiovascular AssessmentCardiovascular DiseaseCardiovascular RiskCoronary Artery DiseaseFamilial HypercholesterolemiaGenetic RiskCardiovascular Risk MarkersCoronary Artery Calcium ScoreCoronary CalcificationCross-sectional Correlation StudyFamily Health HistoryHeterozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaPremature Coronary Artery Disease
Background: Determinants of coronary artery calcification (CAC) prevalence and severity in heterozygous familial hypercholesterolemia (HeFH) remain understudied. The objective of this cross-sectional study was to investigate correlates of CAC in patients with HeFH. Methods: A CAC score was calculated by a noncontrast computed tomography scan in women (n 68) and men (n 78) with genetically defined HeFH. We classified CAC prevalence and severity using 3 categories: CAC score 0 Agatston Unit (AU), CAC score 1-100 AU, and CAC score > 100 AU. Information on potential correlates of CAC including familial and personal health history, cardiovascular risk factors, lipid-lowering medication, and lifestyle habits was collected. R ESUM E Contexte : Les d eterminants de la pr evalence et de la s ev erit e de la calcification des artres coronaires (CAC) dans l'hypercholest erol emie familiale h et erozygote (HFHe) demeurent peu etudi es. L'objectif de cette etude transversale etait d'identifier les corr elats de la CAC chez des patients atteints d'HFHe. M ethodologie : Un score calcique coronarien (SCC) a et e calcul e par un examen de tomodensitom etrie sans contraste chez des femmes (n 68) et des hommes (n 78) avec HFHe g en etiquement d efinie. Nous avons class e la pr evalence et la gravit e de la CAC en trois cat egories : SCC 0 unit e d'Agatston (UA), SCC 1 100 UA et SCC > 100 UA. Des renseignements ont et e recueillis sur des corr elats Heterozygous (He) familial hypercholesterolemia (FH) is an inherited, autosomal dominant disease caused by genetic mutations in the low-density lipoprotein (LDL) receptor (LDLR), apolipoprotein B (apo B), or proprotein convertase subtilisin/kexin type 9. 1 By disrupting the normal clearance of LDLs from the plasma, these mutations cause a marked hypercholesterolemia across the lifespan. HeFH's main clinical feature is a 2-to 3-fold increase in plasma LDL-cholesterol (LDL-C) concentrations, typically ranging from 5.0 to 14.0 mmol/L. If untreated, individuals with HeFH face a 10-to 20-fold increased risk of coronary heart disease (CHD) compared with unaffected individuals, and CHD usually occurs prematurely before the age of 55 years. HeFH is estimated to affect 1 in 310 individuals according to most recent estimates. 2,3 Worldwide, HeFH is the most prevalent genetic disorder, causing premature coronary events and deaths. 1
31
Alternative Dietary Indices Both Strongly Predict Risk of Chronic Disease
Stephanie E. Chiuve, Teresa T. Fung, Eric B. Rimm et al. · Journal of Nutrition · 2012 · 1.9K citations · Full text
Lipoprotein(a) as a cardiovascular risk factor: current status
Børge G. Nordestgaard, M. John Chapman, Kausik K. Ray et al. · European Heart Journal · 2010 · 1.8K citations · Full text